Argenx, the Dutch biotechnology company best known for its blockbuster FcRn blocker Vyvgart, announced on July 27 that it has agreed to acquire Forte Biosciences for approximately $2.2 billion in cash. The deal gives Argenx control of FB-201, a differentiated anti-CD122 antibody currently in Phase 2 development for atopic dermatitis and other immune-mediated inflammatory conditions. For pharmaceutical suppliers and contract manufacturers, the acquisition signals a significant new investment in a target class that has recently attracted interest from multiple developers, with broad implications for biologics API demand and specialized manufacturing capacity across the immunology supply chain.

CD122, also known as the interleukin-2 receptor beta subunit, plays a critical role in the function of regulatory T cells and natural killer cells. Unlike broad immunosuppressive approaches that broadly dampen the immune system, selectively targeting CD122 aims to modulate the immune response by restoring balance between effector and regulatory immune cell populations. Forte's FB-201 has been engineered to preferentially engage CD122 in a manner that enhances regulatory T cell activity while minimizing effects on NK cells, potentially offering a more refined therapeutic window than existing biologics for autoimmune conditions such as atopic dermatitis, psoriasis, and type 1 diabetes. This differentiated mechanism of action positions FB-201 as a potential first-in-class therapy in a market that AbbVie, Sanofi, and Regeneron have already demonstrated is worth tens of billions of dollars annually.

For API and biologics manufacturers, the Argenx-Forte transaction carries several important supply chain implications. First, the deal expands the pipeline of a company that has already demonstrated rapid commercial scaling capabilities with Vyvgart, which generated over $3.6 billion in net sales in 2025. Argenx has established manufacturing partnerships with major CDMOs including Samsung Biologics and Lonza, and adding FB-201 to the portfolio would require additional biologics manufacturing capacity for a differentiated antibody with potentially broad autoimmune applications. The manufacturing demands of a CD122-targeted antibody with specific Fc engineering characteristics will require process development expertise and analytical capabilities that go beyond standard monoclonal antibody production.

The CD122 target class itself is gaining significant momentum across the pharmaceutical industry. Several other developers are pursuing CD122-directed therapies for conditions including graft-versus-host disease, systemic lupus erythematosus, and type 1 diabetes. If Forte's Phase 2 data validates the CD122 mechanism in atopic dermatitis, it could catalyze further investment in this target class across multiple therapeutic areas, driving demand for specialized antibody manufacturing, cell line development, and process development services. CDMOs with demonstrated experience in manufacturing immune-modulating biologics and Fc-engineered antibodies would be particularly well-positioned to capture this emerging demand as the target class matures toward late-stage clinical development and potential commercialization.

From a manufacturing complexity standpoint, anti-CD122 antibodies like FB-201 require careful process optimization to maintain the binding specificity and Fc engineering characteristics that differentiate them from conventional monoclonal antibodies. The glycosylation profile and binding kinetics must be tightly controlled to achieve the desired immune modulation, placing premium demands on analytical characterization and quality control capabilities throughout the manufacturing process. Suppliers of cell culture media, chromatography resins, analytical reagents for biologics characterization, and single-use bioprocessing systems stand to benefit from the expanded manufacturing activity that would follow a successful Phase 2 program and subsequent pivotal trials.

The acquisition also reflects a broader trend of large biotechnology companies paying premium valuations to access differentiated immunology pipelines with novel mechanisms of action. Argenx's willingness to commit $2.2 billion for a Phase 2-stage asset underscores the strategic value that the industry places on novel immune targets capable of addressing large inflammatory disease markets with significant unmet medical need. For API intermediates and raw material suppliers, this signals sustained investment in biologics manufacturing infrastructure, with potential orders for single-use bioreactor systems, filtration units, and downstream processing equipment extending well into 2027 and beyond as Argenx advances FB-201 through clinical development.

Argenx has indicated that the acquisition is expected to close in the fourth quarter of 2026, subject to customary regulatory approvals and standard closing conditions. The company plans to advance FB-201 into pivotal studies across multiple autoimmune indications, which would significantly expand the manufacturing footprint required to support both clinical supply and eventual commercial launch. For pharmaceutical suppliers and CDMO partners, this represents a meaningful near-term capacity planning opportunity as Argenx integrates Forte's pipeline and manufacturing requirements into its existing global production network, which already spans multiple continents and includes both in-house and outsourced capabilities.

The deal also raises competitive dynamics for other companies pursuing immune-modulating therapies in the atopic dermatitis space. Sanofi recently discontinued its anti-OX40L antibody amlitelimab for eczema following mixed Phase 2b results, while AbbVie continues to expand its immunology franchise with Rinvoq. Argenx's entry with a differentiated CD122 mechanism of action could intensify the race for next-generation immunology treatments, further driving demand for specialized biologics API manufacturing capacity across the pharmaceutical supply chain and reinforcing the strategic importance of advanced antibody engineering and manufacturing capabilities for companies competing in the autoimmune disease market.